United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Business Wire•22/10/2026•07:00 ET
0
Key Highlights
- ➤United Therapeutics authorized up to $2 billion in additional common-stock repurchases through October 21, 2027
- ➤New authorization will not reduce capacity under the ongoing September 2026 accelerated share repurchase
- ➤Repurchases may use ASRs, open-market transactions, private deals, or other methods
- ➤Program requires no minimum purchases and remains subject to company discretion and market conditions
Expert Statements
James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics
“We have the balance sheet and free cash flow to fund our long-term ambitions and the confidence to act decisively when our own shares represent a compelling investment.”
James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics
“This authorization is a clear reflection of our deep conviction in the future of our company, our disciplined approach to capital allocation, and our commitment to delivering durable long-term value for shareholders.”
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors has authorized a new share repurchase program for up to $2 billion of the company’s common stock, available through October 21, 2027.
Get started
Create a free account to read the full story.